This dysregulation is most commonly caused by somatic, gain-of-function point mutations in key upstream nodes, particularly the RAS (e.g., KRAS, NRAS) and RAF (e.g., BRAF) families of proto-oncogenes, as comprehensively documented in large-scale cancer genome analyses [142, 143]. This evidence concerns the gene KRAS and cancer.